These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9309129)

  • 1. [p53].
    Takahashi R
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1381-5. PubMed ID: 9309129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53.
    Shan B; Morris GF
    Exp Cell Res; 2005 Apr; 305(1):10-22. PubMed ID: 15777783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F; Bay JO; Dionet C; Verrelle P
    Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage.
    Jin S; Fan F; Fan W; Zhao H; Tong T; Blanck P; Alomo I; Rajasekaran B; Zhan Q
    Oncogene; 2001 May; 20(21):2683-90. PubMed ID: 11420680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.
    Huang S; Liu LN; Hosoi H; Dilling MB; Shikata T; Houghton PJ
    Cancer Res; 2001 Apr; 61(8):3373-81. PubMed ID: 11309295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
    Mendoza-Rodríguez CA; Cerbón MA
    Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells.
    Cayrol C; Knibiehler M; Ducommun B
    Oncogene; 1998 Jan; 16(3):311-20. PubMed ID: 9467956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation.
    Itoshima T; Fujiwara T; Waku T; Shao J; Kataoka M; Yarbrough WG; Liu TJ; Roth JA; Tanaka N; Kodama M
    Clin Cancer Res; 2000 Jul; 6(7):2851-9. PubMed ID: 10914734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Loging WT; Reisman D
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YY1 binding to a subset of p53 DNA-target sites regulates p53-dependent transcription.
    Yakovleva T; Kolesnikova L; Vukojević V; Gileva I; Tan-No K; Austen M; Lüscher B; Ekström TJ; Terenius L; Bakalkin G
    Biochem Biophys Res Commun; 2004 May; 318(2):615-24. PubMed ID: 15120643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas.
    Divan A; Lawry J; Dunsmore IR; Parsons MA; Royds JA
    Cancer Res; 2001 Apr; 61(7):3157-63. PubMed ID: 11306502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA binding and selective gene induction by different forms of the p53 protein.
    Mayelzadeh F; Martinez JD
    Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53: an overview of over two decades of study.
    Cheah PL; Looi LM
    Malays J Pathol; 2001 Jun; 23(1):9-16. PubMed ID: 16329542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.